(c) 2024 PillSync.com

Metoprolol Tartrate 25 mg

1 INDICATIONS AND USAGE Metoprolol tartrate tablets are a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and Myocardial Infarctions. ( 1.1 ) Angina Pectoris. ( 1.2 ) Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute Myocardial Infarction in hemodynamically stable patients ( 1.3 ) 1.1 Hypertension Metoprolol tartrate tablets are indicated for the treatment of Hypertension in adult patients, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and Myocardial Infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in Myocardial Infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe Hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their Hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Metoprolol tartrate tablets may be administered with other antihypertensive agents. 1.2 Angina Pectoris Metoprolol tartrate tablets are indicated in the long-term treatment of Angina Pectoris, to reduce angina attacks and to improve exercise tolerance. 1.3 Myocardial Infarction Metoprolol tartrate tablets are indicated in the treatment of hemodynamically stable patients with definite or suspected acute Myocardial Infarction to reduce cardiovascular mortality when used alone or in conjunction with intravenous metoprolol.

sun pharmaceutical industries, inc.


5 years ago ROUND WHITE 1 Metoprolol Tartrate 25 mg

ROUND WHITE 1

5 years ago ROUND WHITE 1 Metoprolol Tartrate 25 mg

1 ROUND WHITE

16 HOW SUPPLIED/STORAGE AND HANDLING

METOPROLOL TARTRATE Tablets, USP are available containing 25 mg, 50 mg, or 100 mg of

METOPROLOL TARTRATE, USP. Tablets 25 mg -white, circular, film coated tablets debossed with "|" on one side and plain on the other side Bottles of 30 ..................NDC 57664-506-54 Bottles of 90 ..................NDC 57664-506-59 Bottles of 100 ................NDC 57664-506-52 Bottles of 1000 ..............NDC 57664-506-58 Tablets 50 mg - round, white film coated tablets with "477" debossed on one side and scored on the other side Bottles of 100 ................NDC 57664-477-52 Bottles of 1000...............NDC 57664-477-58 Tablets, 50 mg - capsule-shaped, biconvex, white, scored (debossed 166) Bottles of 100 ................NDC 57664-166-52 Bottles of 1000 ..............NDC 57664-166-58 Tablets, 100 mg - round-shaped, film coated, white colored tablets debossed with '162' on one side and 'scored' on the other side. Bottles of 90 ...................NDC 57664-162-59 Bottles of 100 .................NDC 57664-162-52 Bottles of 1000 ...............NDC 57664-162-58 Tablets, 100 mg - capsule-shaped, biconvex, white, scored (debossed 167) Bottles of 90....................NDC 57664-167-59 Bottles of 100 .................NDC 57664-167-52 Bottles of 1000 ...............NDC 57664-167-58 Samples, when available, are identified by the word SAMPLE appearing on each bottle. Storage: Store at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) [See USP Controlled Room Temperature]. Dispense in tight, light-resistant container (USP). Protect from Moisture.


More pills like ROUND 1












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site